{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T20:30:51Z","timestamp":1790973051252,"version":"4.1.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T00:00:00Z","timestamp":1594684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T00:00:00Z","timestamp":1594684800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100016396","name":"French Association of Urology","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100016396","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["World J Urol"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s00345-020-03329-2","type":"journal-article","created":{"date-parts":[[2020,7,14]],"date-time":"2020-07-14T13:50:08Z","timestamp":1594734608000},"page":"4055-4065","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["PD-L1 expression and pattern of immune cells in pre-treatment specimens are associated with disease-free survival for HR-NMIBC undergoing BCG treatment"],"prefix":"10.1007","volume":"39","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2412-146X","authenticated-orcid":false,"given":"Mathieu","family":"Roumigui\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Comp\u00e9rat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9onor","family":"Chaltiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois Xavier","family":"Nouhaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregory","family":"Verhoest","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Masson-Lecomte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Colin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Audenet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Hou\u00e9d\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Larr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanguelos","family":"Xylinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Brunelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanne","family":"Piana-Thomassin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliette","family":"Cotte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9raldine","family":"Pignot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"Neuzillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,14]]},"reference":[{"key":"3329_CR1","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.eururo.2012.07.033","volume":"63","author":"M Burger","year":"2013","unstructured":"Burger M, Catto JW, Dalbagni G et al (2013) Epidemiology and risk factors of urothelial bladder cancer. Eur Urol 63:234\u2013241","journal-title":"Eur Urol"},{"key":"3329_CR2","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/j.eururo.2016.05.041","volume":"71","author":"M Babjuk","year":"2017","unstructured":"Babjuk M, Bohle A, Burger M et al (2017) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 71:447\u2013461","journal-title":"Eur Urol"},{"key":"3329_CR3","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.eururo.2009.06.028","volume":"56","author":"BW van Rhijn","year":"2009","unstructured":"van Rhijn BW, Burger M, Lotan Y et al (2009) Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol 56:430\u2013442","journal-title":"Eur Urol"},{"key":"3329_CR4","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/nature13954","volume":"515","author":"PC Tumeh","year":"2014","unstructured":"Tumeh PC, Harview CL, Yearley JH et al (2014) PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 515:568\u2013571","journal-title":"Nature"},{"key":"3329_CR5","doi-asserted-by":"publisher","first-page":"2304","DOI":"10.1056\/NEJMoa1613683","volume":"376","author":"J Bellmunt","year":"2017","unstructured":"Bellmunt J, Bajorin DF (2017) Pembrolizumab for advanced urothelial carcinoma. N Engl J Med 376:2304","journal-title":"N Engl J Med"},{"key":"3329_CR6","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","volume":"387","author":"JE Rosenberg","year":"2016","unstructured":"Rosenberg JE, Hoffman-Censits J, Powles T et al (2016) Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387:1909\u20131920","journal-title":"Lancet"},{"key":"3329_CR7","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/S0140-6736(17)33297-X","volume":"391","author":"T Powles","year":"2018","unstructured":"Powles T, Duran I, van der Heijden MS et al (2018) Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. Lancet 391:748\u2013757","journal-title":"Lancet"},{"key":"3329_CR8","doi-asserted-by":"publisher","first-page":"4502","DOI":"10.1200\/JCO.2016.34.15_suppl.4502","volume":"34","author":"C Massard","year":"2016","unstructured":"Massard C, Gordon MS, Sharma S et al (2016) Safety and efficacy of durvalumab (MEDI4736), a PD-L1 antibody, in urothelial bladder cancer. J Clin Oncol 34:4502\u20134502","journal-title":"J Clin Oncol"},{"key":"3329_CR9","doi-asserted-by":"publisher","first-page":"4502","DOI":"10.1200\/jco.2015.33.15_suppl.4502","volume":"33","author":"ER Plimack","year":"2015","unstructured":"Plimack ER, Bellmunt J, Gupta S et al (2015) Pembrolizumab (MK-3475) for advanced urothelial cancer: updated results and biomarker analysis from KEYNOTE-012. J Clin Oncol 33:4502\u20134502","journal-title":"J Clin Oncol"},{"key":"3329_CR10","doi-asserted-by":"publisher","first-page":"S46","DOI":"10.1016\/j.purol.2018.07.283","volume":"28","author":"M Roupret","year":"2018","unstructured":"Roupret M, Neuzillet Y, Pignot G et al (2018) French ccAFU guidelines\u2014update 2018\u20132020: bladder cancer. Prog Urol 28:S46\u2013S78","journal-title":"Prog Urol"},{"key":"3329_CR11","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1056\/NEJMoa1200694","volume":"366","author":"JR Brahmer","year":"2012","unstructured":"Brahmer JR, Tykodi SS, Chow LQ et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455\u20132465","journal-title":"N Engl J Med"},{"key":"3329_CR12","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1038\/nm730","volume":"8","author":"H Dong","year":"2002","unstructured":"Dong H, Strome SE, Salomao DR et al (2002) Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med 8:793\u2013800","journal-title":"Nat Med"},{"key":"3329_CR13","doi-asserted-by":"publisher","first-page":"4800","DOI":"10.1158\/1078-0432.CCR-08-0731","volume":"14","author":"SA Boorjian","year":"2008","unstructured":"Boorjian SA, Sheinin Y, Crispen PL et al (2008) T-cell coregulatory molecule expression in urothelial cell carcinoma: clinicopathologic correlations and association with survival. Clin Cancer Res 14:4800\u20134808","journal-title":"Clin Cancer Res"},{"issue":"6","key":"3329_CR14","doi-asserted-by":"publisher","first-page":"1517\u20131524.https","DOI":"10.1007\/s00345-019-02896-3","volume":"38","author":"C Delcourt","year":"2020","unstructured":"Delcourt C, Gemival P, Nouhaud FX et al (2020) Clinical interest of PD-L1 immuno-histochemistry expression as a predictive factor of Bacillus Calmette Guerin (BCG) efficacy in refractory high-risk non-muscle-invasive bladder cancer (NMIBC). World J Urol 38(6):1517\u20131524. https:\/\/doi.org\/10.1007\/s00345-019-02896-3","journal-title":"World J Urol"},{"key":"3329_CR15","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1158\/1078-0432.CCR-19-1920","volume":"26","author":"M Kates","year":"2020","unstructured":"Kates M, Matoso A, Choi W et al (2020) Adaptive immune resistance to intravesical BCG in non-muscle invasive bladder cancer: implications for prospective BCG-unresponsive trials. Clin Cancer Res 26:882\u2013891","journal-title":"Clin Cancer Res"},{"key":"3329_CR16","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s00262-017-2093-9","volume":"67","author":"J Breyer","year":"2018","unstructured":"Breyer J, Wirtz RM, Otto W et al (2018) High PDL1 mRNA expression predicts better survival of stage pT1 non-muscle-invasive bladder cancer (NMIBC) patients. Cancer Immunol Immunother 67:403\u2013412","journal-title":"Cancer Immunol Immunother"},{"key":"3329_CR17","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1245\/s10434-018-6498-2","volume":"25","author":"K Fukumoto","year":"2018","unstructured":"Fukumoto K, Kikuchi E, Mikami S et al (2018) Clinical role of programmed cell death-1 expression in patients with non-muscle-invasive bladder cancer recurring after initial bacillus calmette-guerin therapy. Ann Surg Oncol 25:2484\u20132491","journal-title":"Ann Surg Oncol"},{"key":"#cr-split#-3329_CR18.1","doi-asserted-by":"crossref","unstructured":"Balar AVKG, Uchio EM, et al (2019) Keynote 057: Phase II trial of pembrolizumab (pembro) for patients (pts) with high-risk","DOI":"10.1200\/JCO.2019.37.7_suppl.350"},{"key":"#cr-split#-3329_CR18.2","doi-asserted-by":"crossref","unstructured":"(HR) nonmuscle invasive bladder cancer (NMIBC) unresponsive to bacillus Calmette Gu\u00e9rin (BCG). J Clin Oncol 2019;37 (7_suppl):350","DOI":"10.1200\/JCO.2019.37.7_suppl.350"},{"key":"3329_CR19","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/S0022-5347(17)35678-1","volume":"150","author":"TL Ratliff","year":"1993","unstructured":"Ratliff TL, Ritchey JK, Yuan JJ et al (1993) T-cell subsets required for intravesical BCG immunotherapy for bladder cancer. J Urol 150:1018\u20131023","journal-title":"J Urol"},{"key":"3329_CR20","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1016\/S0022-5347(17)37668-1","volume":"147","author":"S Prescott","year":"1992","unstructured":"Prescott S, James K, Hargreave TB et al (1992) Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall. J Urol 147:1636\u20131642","journal-title":"J Urol"},{"key":"3329_CR21","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1084\/jem.189.5.753","volume":"189","author":"RE Toes","year":"1999","unstructured":"Toes RE, Ossendorp F, Offringa R et al (1999) CD4 T cells and their role in antitumor immune responses. J Exp Med 189:753\u2013756","journal-title":"J Exp Med"},{"key":"3329_CR22","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1172\/JCI0217214","volume":"110","author":"WY Ho","year":"2002","unstructured":"Ho WY, Yee C, Greenberg PD (2002) Adoptive therapy with CD8 (+) T cells: it may get by with a little help from its friends. J Clin Invest 110:1415\u20131417","journal-title":"J Clin Invest"},{"key":"3329_CR23","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1200\/JCO.2008.18.7229","volume":"27","author":"P Salama","year":"2009","unstructured":"Salama P, Phillips M, Grieu F et al (2009) Tumor-infiltrating FOXP3\u2009+\u2009T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 27:186\u2013192","journal-title":"J Clin Oncol"},{"key":"3329_CR24","doi-asserted-by":"publisher","first-page":"39916","DOI":"10.18632\/oncotarget.9537","volume":"7","author":"R Pichler","year":"2016","unstructured":"Pichler R, Fritz J, Zavadil C et al (2016) Tumor-infiltrating immune cell subpopulations influence the oncologic outcome after intravesical Bacillus Calmette-Guerin therapy in bladder cancer. Oncotarget 7:39916\u201339930","journal-title":"Oncotarget"},{"key":"3329_CR25","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s00345-015-1615-3","volume":"34","author":"T Horn","year":"2016","unstructured":"Horn T, Laus J, Seitz AK et al (2016) The prognostic effect of tumour-infiltrating lymphocytic subpopulations in bladder cancer. World J Urol 34:181\u2013187","journal-title":"World J Urol"},{"key":"3329_CR26","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1111\/j.1464-410X.2010.10020.x","volume":"108","author":"ME Winerdal","year":"2011","unstructured":"Winerdal ME, Marits P, Winerdal M et al (2011) FOXP3 and survival in urinary bladder cancer. BJU Int 108:1672\u20131678","journal-title":"BJU Int"},{"key":"3329_CR27","doi-asserted-by":"publisher","first-page":"1439","DOI":"10.1038\/s41598-020-58351-6","volume":"10","author":"H Li","year":"2020","unstructured":"Li H, Zhang Q, Shuman L et al (2020) Evaluation of PD-L1 and other immune markers in bladder urothelial carcinoma stratified by histologic variants and molecular subtypes. Sci Rep 10:1439","journal-title":"Sci Rep"},{"key":"3329_CR28","doi-asserted-by":"publisher","first-page":"e172411","DOI":"10.1001\/jamaoncol.2017.2411","volume":"3","author":"T Powles","year":"2017","unstructured":"Powles T, O\u2019Donnell PH, Massard C et al (2017) Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1\/2 OPEN-LABEL STUDY. JAMA Oncol 3:e172411","journal-title":"JAMA Oncol"},{"key":"3329_CR29","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1002\/cncr.22588","volume":"109","author":"BA Inman","year":"2007","unstructured":"Inman BA, Sebo TJ, Frigola X et al (2007) PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression. Cancer 109:1499\u20131505","journal-title":"Cancer"}],"container-title":["World Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-020-03329-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00345-020-03329-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00345-020-03329-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,5]],"date-time":"2021-11-05T15:02:53Z","timestamp":1636124573000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00345-020-03329-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,14]]},"references-count":30,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["3329"],"URL":"https:\/\/doi.org\/10.1007\/s00345-020-03329-2","relation":{},"ISSN":["0724-4983","1433-8726"],"issn-type":[{"value":"0724-4983","type":"print"},{"value":"1433-8726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,14]]},"assertion":[{"value":"1 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 June 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}